NPCE
NeuroPace Inc
NASDAQ · Healthcare · Medical - Devices · US
$12.30
−5.46%Year over year
Reported trailing growth
- Revenue
- +11.6%
- EBITDA
- +26.4%
- EBIT
- +24.1%
- EPS
- +31.9%
- Free cash flow
- +29.3%
- Operating cash flow
- +30.1%
Forward estimates
Based on analyst estimates
- Revenue
- +17.3%
- EBITDA
- +63.7%
- EPS
- +37.2%
Three-year CAGR
- Revenue
- +30.0%
- EBITDA
- +27.2%
- EBIT
- +24.6%
- Net income
- +20.9%
- EPS
- +29.0%
- Free cash flow
- +37.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026